Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F5 Inc (FFIV) vs McKesson Corporation (MCK) Price & Performance

McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

F5 Inc vs McKesson Corporation — how do they compare? F5 Inc trades at $460.99 (market cap $26.42B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 4× F5 Inc's market cap, and McKesson Corporation pays a 0.41% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and McKesson Corporation for 74 Days on average.

FFIVMCK
Market Cap
$26.42B$106.14B
Volume
454,868794,405
Sector
TechnologyHealth
52-Week High
$469.79$995.69
52-Week Low
$223.99$725.17
Typical Hold Time
38 Days74 Days
Enterprise Value
$25.06B$112.67B
Dividend Yield
—0.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F5 Inc

F5 (FFIV) trades at $466.65, down 0.67% on the day, as the stock consolidates near recent highs following strong year-to-date performance. The company continues to demonstrate robust fundamentals with revenue growth accelerating to $3.09 billion in 2025 and net income reaching $692 million, representing a 22.4% margin. Recent analyst recognition as a leader in WAAP platforms and AI security positions F5 well in the growing cybersecurity market. Technical indicators show the stock trading near resistance at $468 with bullish moving averages but overbought RSI readings suggesting potential near-term consolidation.

F5 presents a compelling growth story with consistent earnings beats and expanding profitability, though current valuation multiples appear elevated. The main investment opportunity lies in the company's leadership in application security and AI-driven solutions, while risks include competitive pressures and execution challenges in maintaining growth momentum. Analyst consensus remains cautiously optimistic with a $416.60 price target, indicating potential downside from current levels despite the positive business trajectory.

McKesson Corporation

McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.

Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FFIV

No sentiment data available yet.

MCK
40% Buy60% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About F5 Inc

F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.

Read more on FFIV →

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →